Details

Autor(en) / Beteiligte

• Gouveia Buff Passone, Caroline
• Giani, Elisa
• Vaivre‐Douret, Laurence
• Kariyawasam, Dulanjalee
• Berdugo, Marianne
• Garcin, Laure
• Beltrand, Jacques
• Bernardo, Wanderley Marques
• Polak, Michel

Titel

Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta‐analyses

Ist Teil von

• Pediatric diabetes, 2022-09, Vol.23 (6), p.675-692

Ort / Verlag

Former Munksgaard: John Wiley & Sons A/S

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Objective In monogenic diabetes due to KCNJ11 and ABCC8 mutations that impair KATP‐ channel function, sulfonylureas improve long‐term glycemic control. Although KATP channels are extensively expressed in the brain, the effect of sulfonylureas on neurological function has varied widely. We evaluated published evidence about potential effects of sulfonylureas on neurological features, especially epilepsy, cognition, motor function and muscular tone, visuo‐motor integration, and attention deficits in children and adults with KCNJ11 and ABCC8‐related neonatal‐onset diabetes mellitus. Research Design and Methods We conducted a systematic review and meta‐analyses of the literature (PROSPERO, CRD42021254782), including individual‐patient data, according to PRISMA, using RevMan software. We also graded the level of evidence. Results We selected 34 of 776 publications. The evaluation of global neurological function before and after sulfonylurea (glibenclamide) treatment in 114 patients yielded a risk difference (RD) of 58% (95%CI, 43%–74%; I2 = 54%) overall and 73% (95%CI, 32%–113%; I2 = 0%) in the subgroup younger than 4 years; the level of evidence was moderate and high, respectively. EEG studies of epilepsy showed a RD of 56% (95%CI, 23%–89%; I2 = 34%) in patients with KCNJ11 mutations, with a high quality of evidence. For hypotonia and motor function, the RDs were 90% (95%CI, 69%–111%; I2 = 0%) and 73% (95%CI, 35%–111%; I2 = 0%), respectively, with a high level of evidence. Conclusions Glibenclamide significantly improved neurological abnormalities in patients with neonatal‐onset diabetes due to KCNJ11 or ABCC8 mutations. Hypotonia was the symptom that responded best. Earlier treatment initiation was associated with greater benefits.